Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.

  title={Enhanced T cell-mediated protection against malaria in human challenges by using the recombinant poxviruses FP9 and modified vaccinia virus Ankara.},
  author={Daniel P. Webster and Susanna J . Dunachie and Jenni M. Vuola and Tamara K Berthoud and Sheila M. Keating and Stephen M Laidlaw and Samuel McConkey and Ian D. Poulton and Laura Andrews and Rikke F. Andersen and Philip Bejon and Geoffrey A. Butcher and Robert E Sinden and Michael A. Skinner and Sarah C. Gilbert and Adrian V. S. Hill},
  journal={Proceedings of the National Academy of Sciences of the United States of America},
  volume={102 13},
  • D. WebsterS. Dunachie A. Hill
  • Published 29 March 2005
  • Biology, Medicine
  • Proceedings of the National Academy of Sciences of the United States of America
Malaria is a major global health problem for which an effective vaccine is required urgently. Prime-boost vaccination regimes involving plasmid DNA and recombinant modified vaccinia virus Ankara-encoding liver-stage malaria antigens have been shown to be powerfully immunogenic for T cells and capable of inducing partial protection against experimental malaria challenge in humans, manifested as a delay in time to patent parasitemia. Here, we report that substitution of plasmid DNA as the priming… 

Figures and Tables from this paper

Prime-boost vectored malaria vaccines: Progress and prospects

Simian adenoviruses have been assessed as priming agents in Adenovirus-MVA regimes in both phase I and phase IIa trials in the UK, based on very promising pre-clinical results showing better immunogenicity and efficacy than previous prime-boost regimes.

Combining Liver- and Blood-Stage Malaria Viral-Vectored Vaccines: Investigating Mechanisms of CD8+ T Cell Interference

Investigation of the utility of the same immunization regimen when combining viral vectored vaccines expressing the 42-kDa C terminus of the blood-stage Ag merozoite surface protein 1 and the pre-erythrocytic Ag circumsporozoite protein in the Plasmodium yoelii mouse model finds that vaccine coadministration leads to maintained Ab responses and efficacy against blood- stage infection, but reduced secondary CD8+ T cell responses against both Ags.

Prime-boost vaccination with chimpanzee adenovirus and modified vaccinia Ankara encoding TRAP provides partial protection against Plasmodium falciparum infection in Kenyan adults

Vaccination with the recombinant viral vectors chimpanzee adenovirus 63 followed by modified vaccinia Ankara both encoding the malaria sequence ME-TRAP conferred 67% protection against infection with

Combination of Protein and Viral Vaccines Induces Potent Cellular and Humoral Immune Responses and Enhanced Protection from Murine Malaria Challenge

For diseases such as malaria, using combinations of partially effective vaccines may offer a more rapid route to achieving deployable levels of efficacy than individual vaccine strategies.

Phase Ia Clinical Evaluation of the Safety and Immunogenicity of the Plasmodium falciparum Blood-Stage Antigen AMA1 in ChAd63 and MVA Vaccine Vectors

ChAd63-MVA is a promising heterologous prime-boost vaccine strategy that could be applied to numerous other diseases where strong cellular and humoral immune responses are required for protection.



Enhanced T-cell immunogenicity of plasmid DNA vaccines boosted by recombinant modified vaccinia virus Ankara in humans

It is shown that a heterologous prime-boost vaccination regime of DNA either intramuscularly or epidermally, followed by intradermal recombinant modified vaccinia virus Ankara (MVA), induces high frequencies of interferon-γ-secreting, antigen-specific T-cell responses in humans to a pre-erythrocytic malaria antigen, thrombospondin-related adhesion protein (TRAP).

Enhanced immunogenicity for CD8+ T cell induction and complete protective efficacy of malaria DNA vaccination by boosting with modified vaccinia virus Ankara

DNA priming followed by MVA boosting may provide a general immunization regime for induction of high levels of CD8+ T cells and was abrogated when the order of immunization was reversed.

Enhanced CD8+ T Cell Immune Responses and Protection Elicited against Plasmodium berghei Malaria by Prime Boost Immunization Regimens Using a Novel Attenuated Fowlpox Virus1

This immunization regimen elicited substantial protection against a stringent liver-stage challenge with P. berghei and was more immunogenic and protective than DNA/MVA prime/boost immunization, but further improvement was not achieved by sequential immunization with a DNA vaccine, FP9, and MVA.

Enhanced T-Cell Immunogenicity and Protective Efficacy of a Human Immunodeficiency Virus Type 1 Vaccine Regimen Consisting of Consecutive Priming with DNA and Boosting with Recombinant Fowlpox Virus

These studies suggest a safe strategy for the enhanced generation of T-cell-mediated protective immunity to HIV-1, and a consecutive immunization strategy involving priming with DNA and boosting with rFPV vaccines encoding common HIV- 1 antigens is evaluated.

Enhanced Immunogenicity of CD4+ T-Cell Responses and Protective Efficacy of a DNA-Modified Vaccinia Virus Ankara Prime-Boost Vaccination Regimen for Murine Tuberculosis

Heterologous prime-boost regimens boost CD4+ as well as CD8+T-cell responses, and the use of heterologous constructs encoding the same antigen(s) may improve the immunogenicity and protective efficacy of DNA vaccines against tuberculosis and other diseases.

Effective Induction of Simian Immunodeficiency Virus-Specific Cytotoxic T Lymphocytes in Macaques by Using a Multiepitope Gene and DNA Prime-Modified Vaccinia Virus Ankara Boost Vaccination Regimen

It is demonstrated clearly that the DNA prime-MVA boost regimen is an effective protocol for induction of CTLs in macaques, and the correlations of tetramer staining of peripheral blood lymphocytes with CTL killing in vitro and postchallenge control of viremia are discussed.

Differential Immunogenicity of Various Heterologous Prime-Boost Vaccine Regimens Using DNA and Viral Vectors in Healthy Volunteers1

Describing cell-mediated immune responses induced by different prime-boost combinations where all vectors encode a multiepitope string fused to the pre-erythrocytic Ag thrombospondin-related adhesion protein shows that these different vectors need to be used in a specific order for an optimal ex vivo IFN-γ response.

Phase I/IIa safety, immunogenicity, and efficacy trial of NYVAC-Pf7, a pox-vectored, multiantigen, multistage vaccine candidate for Plasmodium falciparum malaria.

While antibody responses were generally poor, cellular immune responses were detected in >90% of the volunteers and there was a significant delay in time to parasite patency in the groups of volunteers who received either the low or high dose of vaccine compared with control volunteers.

Boosting with recombinant vaccinia increases immunogenicity and protective efficacy of malaria DNA vaccine.

The observation that priming with PyCSP DNA and boosting with vaccinia-PyCSP is more immunogenic and protective than immunizing with Py CSP DNA alone supports consideration of a similar sequential immunization approach in humans.

The Complexity of Protective Immunity Against Liver-Stage Malaria1 2

Investigation of mechanisms of protective immunity induced by immunization with different vaccine delivery systems in genetically distinct inbred strains, genetically modified mice, and outbred mice establishes that there is a marked diversity of T cell-dependent immune responses that mediate sterile protective immunity against liver-stage malaria.